Quarterly ResultAug 6, 2026, 07:27 AM
Precision BioSciences Q2: HBV cccDNA Eliminated, Cash to 2028
AI Summary
Precision BioSciences reported a Q2 2026 net loss of $32.7 million, with a cash balance of $112.4 million, expected to fund operations through 2028. The company announced significant clinical progress for PBGENE-HBV, demonstrating the first clinical biopsy evidence of direct cccDNA elimination and sustained pgRNA loss in 100% of evaluable patients. Additionally, PBGENE-DMD is actively recruiting patients for its Phase 1/2 trial, with initial safety data targeted for year-end 2026.
Key Highlights
- Q2 2026 net loss was $32.7 million, or $(1.26) per share.
- Cash, cash equivalents, and restricted cash totaled $112.4 million as of June 30, 2026.
- PBGENE-HBV achieved a 1-log reduction in cccDNA in one patient after two administrations.
- PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients.
- No dose-limiting toxicities observed in 16 patients across five cohorts for PBGENE-HBV.
- Cash runway is expected to fund data milestones for PBGENE-HBV and PBGENE-DMD through 2028.
- Research and development expenses decreased to $12.4 million for Q2 2026.
- TG Therapeutics made a $7.5 million clinical milestone payment for azer-cel.
Price Impact
More from DTIL